SF0166
Modify Date: 2024-01-02 20:36:00
SF0166 structure
|
Common Name | SF0166 | ||
|---|---|---|---|---|
| CAS Number | 1621332-91-9 | Molecular Weight | 475.497 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C23H27F2N5O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SF0166SF0166 is a topically administered αvβ3 integrin antagonist, inhibits integrin-ligand interactions with IC50 of 0.6 nM to 13 nM for human αvβ3, αvβ6, and αvβ8; inhibits cellular adhesion to vitronectin across human, rat, rabbit, and dog cell lines with IC50 of 7.6 pM-76 nM; significantly decreases neovascularization in the oxygen-induced retinopathy mouse models. Other Indication Phase 2 Clinical |
| Name | SF0166 |
|---|
| Description | SF0166 is a topically administered αvβ3 integrin antagonist, inhibits integrin-ligand interactions with IC50 of 0.6 nM to 13 nM for human αvβ3, αvβ6, and αvβ8; inhibits cellular adhesion to vitronectin across human, rat, rabbit, and dog cell lines with IC50 of 7.6 pM-76 nM; significantly decreases neovascularization in the oxygen-induced retinopathy mouse models. Other Indication Phase 2 Clinical |
|---|---|
| References | References 1. Askew BC, et al. J Pharmacol Exp Ther. 2018 May 31. pii: jpet.118.248427. View Related Products by Target Integrin Other Indication |
| Molecular Formula | C23H27F2N5O4 |
|---|---|
| Molecular Weight | 475.497 |